loader
Please Wait
Applying Filters...
menu
    • menu

    Digital Content for Brepocitinib

    Client Email Product
    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    Bora Pharmaceuticals- Making success more certain.

    Virtual Booth

    Contact Supplier

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.

    Virtual Booth

    Contact Supplier

    Axplora- The partner of choice for complex APIs.

    Virtual Booth

    Contact Supplier

    Fareva is a one-stop-shop for API/HPAPI, OSD & Sterile products, is USFDA, EMA and PMDA-inspected and has multiple NDA & ANDA filings.

    Virtual Booth

    Contact Supplier

    Menu

    Brepocitinib

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Priovant Gets FDA Fast Track For Brepocitinib In NIU
    Priovant Gets FDA Fast Track For Brepocitinib In NIU

    23 Sep 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/priovant-therapeutics-announces-receipt-of-fast-track-designation-from-fda-for-brepocitinib-in-non-anterior-non-infectious-uveitis-niu--start-of-enrollment-of-brepocitinib-phase-3-niu-program-302254625.html

    PR NEWSWIRE
    23 Sep 2024
    Share Share
    Roivant Provides Update on Graves’ Disease Development Program
    Roivant Provides Update on Graves’ Disease Development Program

    09 Sep 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/09/09/2942671/34323/en/Roivant-Provides-Update-on-Graves-Disease-Development-Program.html

    GLOBENEWSWIRE
    09 Sep 2024
    Share Share
    Roivant's anti-inflammatory drug shows promise in mid-stage study
    Roivant's anti-inflammatory drug shows promise in mid-stage study

    03 Apr 2024

    // Bhanvi Satija REUTERS

    https://www.reuters.com/business/healthcare-pharmaceuticals/roivants-anti-inflammatory-drug-succeeds-mid-stage-study-2024-04-02/

    Bhanvi Satija REUTERS
    03 Apr 2024
    Share Share
    Roivant Sciences' lupus drug fails to reduce symptoms in mid-stage study
    Roivant Sciences' lupus drug fails to reduce symptoms in mid-stage study

    28 Nov 2023

    // REUTERS

    https://www.reuters.com/business/healthcare-pharmaceuticals/roivant-sciences-lupus-drug-fails-reduce-symptoms-mid-stage-study-2023-11-27/

    REUTERS
    28 Nov 2023
    Share Share
    Roivant Sciences Reports Financial Results for the First Quarter
    Roivant Sciences Reports Financial Results for the First Quarter

    15 Aug 2022

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2022/08/15/2498069/34323/en/Roivant-Sciences-Reports-Financial-Results-for-the-First-Quarter-Ended-June-30-2022-and-Provides-Business-Update.html

    GLOBENEWSWIRE
    15 Aug 2022
    Share Share